Edition:
India

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

2.62USD
7 Aug 2020
Change (% chg)

$0.02 (+0.77%)
Prev Close
$2.60
Open
$2.64
Day's High
$2.67
Day's Low
$2.55
Volume
483,173
Avg. Vol
1,278,636
52-wk High
$4.38
52-wk Low
$1.14

Select another date:

Sat, May 30 2020

BRIEF-Athersys Says May From Time To Time Issue Up To 35 Mln Shares Of Common Stock In One Or More Offerings

* ATHERSYS INC SAYS MAY FROM TIME TO TIME ISSUE UP TO 35 MILLION SHARES OF COMMON STOCK IN ONE OR MORE OFFERINGS - SEC FILING Source text: (https://bit.ly/36Hc7tO) Further company coverage:

BRIEF-Athersys Reports First Quarter 2020 Results

* THERE WERE NO REVENUES FOR THREE MONTHS ENDED MARCH 31, 2020 COMPARED TO $1.4 MILLION

BRIEF-Athersys Announces Commencement Of Patient Enrollment In The Macovia Study

* ATHERSYS ANNOUNCES COMMENCEMENT OF PATIENT ENROLLMENT IN THE MACOVIA STUDY, A PIVOTAL PHASE 2/3 TRIAL EVALUATING MULTISTEM® CELL THERAPY FOR COVID-19 INDUCED ARDS Source text for Eikon: Further company coverage:

BRIEF-Athersys And University Hospitals Cleveland Medical Center Announce Activation Of First Clinical Site For Macovia Study

* ATHERSYS AND UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER ANNOUNCE ACTIVATION OF FIRST CLINICAL SITE FOR MACOVIA STUDY

BRIEF-Athersys Announces Proposed Public Offering Of Common Stock

* ATHERSYS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-FDA Authorizes Athersys To Initiate A Pivotal Clinical Trial Evaluating Multistem® Cell Therapy In Patients With Covid-19 Induced Acute Respiratory Distress Syndrome

* FDA AUTHORIZES ATHERSYS TO INITIATE A PIVOTAL CLINICAL TRIAL EVALUATING MULTISTEM® CELL THERAPY IN PATIENTS WITH COVID-19 INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-Athersys Reports Q4 Loss Per Share Of $0.06

* ATHERSYS ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2019

Select another date: